Australian academic research programs in the areas of neuroscience, oncology, gastroenterology, and regenerative medicine will benefit from innovation grants announced by Takeda at the 2018 AusBiotech conference.
The company’s new COCKPI-T Australia 2018 research grants program is operated by the company’s Shonan research site in Japan in collaboration with Takeda Australia.
Four successful applicants for the research grants program have been selected from more than 60 applications.
The aim of the grants it to advance therapeutic ideas, targets and technologies in drug discovery by providing support to promising study concepts.
The successful research applicants, each receiving a grant of approximately $100,000, are:
- Mayuresh Korgaonkar, research director, Westmead Institute for Medical Research and University of Sydney (neuroscience);
- Associate professor Trent Woodruff, University of Queensland (neuro-immunology);
- Andrew Greenhill, senior lecturer, Federation University Australia (gastroenterology); and,
- Professor Richard D’Andrea, University of South Australia (oncology) and Dr Nicola Verrills, The University of Newcastle and Hunter Medical Research Institute.
Managing director of Takeda Australia, James Jones, said, “Takeda is pleased to be able to support and encourage high quality Australian research through investment in these early stage programs at various universities.
“The COCKPI-T Australia 2018 program attracted many excellent applications across the therapeutic areas that Takeda focuses on, reaffirming Australia’s strong reputation in innovative academic and clinical research. We congratulate the successful applicants and look forward to their contribution in understanding complex diseases areas .”
Takeda Australia Managing Director James Jones pictured with one of the research grant recipients Associate Professor Trent Woodruff at the University of Queensland.